Cadrenal Therapeutics (NASDAQ:CVKD) Issues Quarterly Earnings Results

Cadrenal Therapeutics (NASDAQ:CVKD) announced its quarterly earnings results on Thursday. The company reported ($2.74) EPS for the quarter, missing the consensus estimate of ($1.71) by ($1.03), Zacks reports.

Cadrenal Therapeutics Price Performance

Shares of NASDAQ:CVKD opened at $19.09 on Friday. The firm has a market capitalization of $34.04 million, a PE ratio of -2.86 and a beta of 1.40. The business has a 50-day moving average of $18.31 and a two-hundred day moving average of $15.03. Cadrenal Therapeutics has a 12 month low of $5.40 and a 12 month high of $22.90.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.